First NHS-Reimbursed Cannabis Prescription for Cancer Chemotherapy Nausea

A cancer patient who failed multiple standard antiemetics became the first known NHS-reimbursed recipient of cannabis flowers, reporting improved nausea, sleep, appetite, and quality of life.

Roberts, Michael et al.·Cureus·2024·PreliminaryCase Report
RTHC-05656Case ReportPreliminary2024RETHINKTHC RESEARCH DATABASErethinkthc.com/research

Quick Facts

Study Type
Case Report
Evidence
Preliminary
Sample
Not reported

What This Study Found

A patient with rectosigmoid adenocarcinoma with lung metastases failed five standard antiemetics. Inhalation of THC-predominant cannabis flowers improved CINV, anxiety, sleep, appetite, mood, and quality of life. NHS England approved an individual funding request.

Key Numbers

Failed 5 standard antiemetics; improved CINV, anxiety, sleep, appetite, mood, and quality of life; first known NHS-reimbursed cannabis flower prescription.

How They Did This

Autobiographical case report with medical data from NHS records, individual funding request forms, and patient-reported outcome measures.

Why This Research Matters

This case documents a viable pathway for NHS patients to access medicinal cannabis through individual funding requests when standard treatments fail.

The Bigger Picture

The NHS reimbursement pathway established here could serve as a precedent for other patients in similar situations.

What This Study Doesn't Tell Us

Single case report. Autobiographical format introduces potential bias. Cannot isolate cannabis effect from placebo.

Questions This Raises

  • ?Will this precedent lead to more individual funding requests for cannabis flowers?
  • ?How does inhaled cannabis compare to oral nabilone for CINV?

Trust & Context

Key Stat:
First known NHS-reimbursed cannabis flower prescription
Evidence Grade:
Single autobiographical case report, but documents a novel administrative pathway.
Study Age:
2024 publication
Original Title:
NHS-Reimbursed Cannabis Flowers for Cancer Palliative Care and the Management of Chemotherapy-Induced Nausea and Vomiting: An Autobiographical Case Report.
Published In:
Cureus, 16(6), e61791 (2024)
Database ID:
RTHC-05656

Evidence Hierarchy

Meta-Analysis / Systematic Review
Randomized Controlled Trial
Cohort / Case-Control
Cross-Sectional / ObservationalSnapshot without intervening
This study
Case Report / Animal Study
What do these levels mean? →

Frequently Asked Questions

Can the NHS prescribe cannabis for chemotherapy nausea?

This case documents the first known NHS-reimbursed prescription of cannabis flowers for CINV. The patient obtained access through an individual funding request after failing five standard antiemetics.

Does cannabis help with chemo nausea when other drugs fail?

In this single case, inhaled THC-predominant cannabis effectively managed chemotherapy nausea while improving sleep, appetite, and quality of life. Clinical trials are needed to confirm.

Read More on RethinkTHC

Cite This Study

RTHC-05656·https://rethinkthc.com/research/RTHC-05656

APA

Roberts, Michael; Brown, Matthew R D; Moreno-Sanz, Guillermo. (2024). NHS-Reimbursed Cannabis Flowers for Cancer Palliative Care and the Management of Chemotherapy-Induced Nausea and Vomiting: An Autobiographical Case Report.. Cureus, 16(6), e61791. https://doi.org/10.7759/cureus.61791

MLA

Roberts, Michael, et al. "NHS-Reimbursed Cannabis Flowers for Cancer Palliative Care and the Management of Chemotherapy-Induced Nausea and Vomiting: An Autobiographical Case Report.." Cureus, 2024. https://doi.org/10.7759/cureus.61791

RethinkTHC

RethinkTHC Research Database. "NHS-Reimbursed Cannabis Flowers for Cancer Palliative Care a..." RTHC-05656. Retrieved from https://rethinkthc.com/research/roberts-2024-nhsreimbursed-cannabis-flowers-for

Access the Original Study

Study data sourced from PubMed, a service of the U.S. National Library of Medicine, National Institutes of Health.

This study breakdown was produced by the RethinkTHC research team. We analyze and report published research findings without making health recommendations. All interpretations are based solely on the published abstract and study data.